Abstract
The prevalence of asthma in the United States is on the rise, and current asthma guidelines recommend prescribing short-acting beta agonists (albuterol) for treatment of reversible airway disease. Government regulations have imposed the transition from albuterol CFC (chlorofluorocarbon) to albuterol HFA (hydrofluroalkane). Prescribers must consider differences between CFC versus HFA inhalers, as well as variations among the available forms of albuterol HFA. Device design, increased cost for branded medication, patient preference, and a host of variables must be considered when deciding among the types of albuterol HFA for a given patient. Pharmacists and clinicians must partner together and recognize that all forms of albuterol are not interchangeable and thus improve asthma management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
